Regulation of apoA-I gene expression: Mechanism of action of estrogen and genistein

Journal of Lipid Research

Volumn 45, Issue 1, 2004, Pages 106-112

  Lamon Fava, Stefania ^a   Micherone, Dale ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Apolipoprotein; Early growth response factor 1; Hepatocyte nuclear factor 3 ; Liver; Mitogen activated protein kinase

Indexed keywords

APOLIPOPROTEIN A1; EARLY GROWTH RESPONSE FACTOR 1; ESTRADIOL; ESTROGEN; FULVESTRANT; GENISTEIN; HEPATOCYTE NUCLEAR FACTOR 3; HEPATOCYTE NUCLEAR FACTOR 3BETA; HIGH DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ESTROGEN ACTIVITY; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROMOTER REGION;

APOLIPOPROTEIN A-I; BASE SEQUENCE; CELL LINE; CELL NUCLEUS; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTROGENS; GENE EXPRESSION REGULATION; GENISTEIN; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS;

EID: 0842282981     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300179-JLR200     Document Type: Article

References (34)

1. Ordovas, J. M., D. K. Cassidy, F. Civeira, C. L. Bisgaier, and E. J. Schaefer. 1989. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J. Biol. Chem. 264: 16339-16342.
2. Lamon-Fava, S., J. M. Ordovas, G. Mandel, T. M. Forte, R. H. Goodman, and E. J. Schaefer. 1987. Secretion of apolipoprotein A-I in lipoprotein particles following transfection of the human apolipoprotein A-I gene into 3T3 cells. J. Biol. Chem. 262: 8944-8947.
3. Rader, D. 2002. High density lipoproteins and atherosclerosis. Am. J. Cardiol. 90: 62i-70i.
4. The Expert Panel. 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285: 2486-2497.
5. Gordon, T., W. P. Castelli, M. C. Hjortland, W. E. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62: 707-714.
6. Genest, J. J., J. R. McNamara, J. M. Ordovas, and E. J. Schaefer. 1992. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J. Am. Coll. Cardiol. 19: 792-802.
7. The Writing Group for the PEPI Trial. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273: 199-208.
8. Schaefer, E. J., D. M. Foster, L. A. Zech, F. T. Lindgren, H. B. J. Brewer, and R. I. Levy. 1983. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal women. J. Clin. Endocrinol. Metab. 57: 262-267.
9. Walsh, B. W., H. Li, and F. M. Sacks. 1994. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J. Lipid Res. 35: 2083-2093.
10. Brinton, E. A. 1996. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein AI and lowers hepatic lipase activity without lowering the catabolic rate. Arterioscler. Thromb. Vasc. Biol. 16: 431-440.
11. Barkhem, T., B. Carlsson, Y. Nilsson, E. Enmark, J. Gustafsson, and S. Nilsson. 2000. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54: 105-112.
12. Scheiber, M., J. Liu, M. Subbiah, R. Rebar, and K. D. Setchell. 2001. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause. 8: 384-392.
13. Sanders, T., T. Dean, D. Grainger, G. Miller, and H. Wiseman. 2002. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta 1 concentrations and hemostatic factors for coronary heart disease in healthy subjects. Am. J. Clin. Nutr. 76: 373-377.
14. Crouse, J. I., T. Morgan, J. Terry, J. Ellis, M. Vitolins, and G. Burke. 1999. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch. Intern. Med. 159: 2070-2076.
15. Lichtenstein, A. H., S. Jalbert, H. Adlercreutz, B. Goldin, H. Rasmussen, E. J. Schaefer, and L. Ausman. 2002. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler. Thromb. Vasc. Biol. 22: 1852-1858.
16. Lamon-Fava, S., J. M. Ordovas, and E. J. Schaefer. 1999. Estrogen increases apolipoprotein (apo) A-I secretion in Hep G2 cells by modulating transcription of the apoA-I gene promoter. Arterioscler. Thromb. Vasc. Biol. 19: 2960-2965.
17. Jin, F. Y., V. S. Kamanna, and M. L. Kashyap. 1998. Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells. Arterioscler. Thromb. Vasc. Biol. 18: 999-1006.
18. Lamon-Fava, S. 2000. Genistein activates apolipoprotein A-I gene expression in the human hepatoma cell line Hep G2. J. Nutr. 130: 2489-2492.
19. Widom, R., J. Ladias, S. Kouidou, and S. K. Karathanasis. 1991. Synergistic interactions between transcription factors control expression of the apolipoprotein A-I gene in liver cells. Mol. Cell. Biol. 11: 677-687.
20. Harnish, D. C., S. Malik, E. Kilbourne, R. Costa, and S. K. Karathanasis. 1996. Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4. J. Biol. Chem. 271: 13621-13628.
21. Harnish, D. C., S. Malik, and S. K. Karathanasis. 1994. Activation of apolipoprotein A-I gene expression by the liver-enriched factor HNF-3. J. Biol. Chem. 269: 28220-28226.
22. Kilbourne, E., R. Widom, D. C. Harnish, S. Malik, and S. K. Karathanasis. 1995. Involvment of early growth response factor Egr-1 in apolipoprotein A-I gene transcription. J. Biol. Chem. 270: 7004-7010.
23. Zhang, X., J-J. Jiao, B. Bhavnani, and S-P. Tam. 2001. Regulation of human apolipoprotein A-I gene expression by equine estrogens. J. Lipid Res. 42: 1789-1880.
24. Harnish, D. C., M. J. Evans, M. S. Scicchitano, R. A. Bhat, and S. K. Karathanasis. 1998. Estrogen regulation of the apolipoprotein AI gene promoter through transcription cofactor sharing. J. Biol. Chem. 273: 9270-9278.
25. Hoppe-Seyler, F., K. Butz, C. Rittmuller, and M. von Knebel Doeberitz. 1991. A rapid microscale procedure for the simultaneous preparation of cytoplasmic RNA, nuclear DNA binding proteins, and enzymatically active luciferase extracts. Nucleic Acids Res. 19: 5080.
26. de Jager, T., T. Pelzer, S. Muller-Botz, A. Imam, J. Muck, and L. Neyses. 2001. Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERK1/2 pathway and serum response elements. J. Biol. Chem. 276: 27873-27880.
27. Barr, D. 1955. Influence of sex and sex hormones upon the development of atheroslerosis and upon the lipoproteins of plasma. J. Chronic Dis. 1: 63-78.
28. Falkenstein, E., H-C. Tillman, M. Christ, M. Feuring, and M. Wehling. 2000. Multiple actions of steroid hormones. A focus on rapid, nongenomic effects. Pharmacol. Rev. 52: 513-555.
29. Zaiou, M., N. Azrolan, T. Hayek, H. Wang, L. Wu, M. Haghpassand, B. Cizman, M. Madaio, J. Milbrandt, and J. Marsh. 1998. The full induction of human apolipoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1. J. Clin. Invest. 101: 1699-1707.
30. Cui, L., N. Schoene, L. Zhu, J. Fanzo, A. Alshatwi, and K. Lei. 2002. Zinc depletion reduced Egr-1 and HNF-3β expression and apolipoprotein A-I promoter activity in Hep G2 cells. Am. J. Physiol. Cell Physiol. 283: C623-C630.
31. Zheng, X-L., S. Matsubara, C. Diao, M. Hollenberg, and N. Wong. 2001. Epidermal growth factor induction of apolipoprotein A-I is mediated by the Ras-MAP kinase cascade and Spl. J. Biol. Chem. 276: 13822-13829.
32. Lo, L., J. Cheng, J. Chiu, B. Wung, Y. Liu, and D. Wang. 2001. Endothelial exposure to hypoxia induces Egr-1 expression involving PKCα-mediated Ras/Raf-1/ERK1/2 pathway. J. Cell. Physiol. 188: 304-312.
33. Yamada, S., Q. Zhu, Y. Aihara, H. Onda, Z. Zhang, L. Yu, L. Jin, Y-J. Si, H. Nishigori, H. Tomura, I. Inoue, A. Morikawa, K. Yamagata, T. Hanafusa, Y. Matsuzawa, and J. Takeda. 2000. Cloning of cDNA and the gene encoding human hepatocyte nuclear factor (HNF)-3β and mutation screening in Japanese subjects with maturity-onset diabetes of the young. Diabetologia. 43: 121-124.
34. Archer, T. K., S-P. Tam, and R. G. Deeley. 1986. Kinetics of estrogen-dependent modulation of apolipoprotein A-I synthesis in human hepatoma cells. J. Biol. Chem. 261: 5067-5074.